Find Clinical Trials & Studies

High-Dose Cisplatin q3Weeks to Low-Dose Cisplatin Weekly With Radiation in Head and Neck Cancer

I'm Interested!
Please call
1-800-641-2422

Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • Sex: Any
  • Age: Adult (18 - 64), Older Adult (65+)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase I
  • Conditions Being Studied:

Study Purpose

This phase II/III trial compares whether cisplatin given weekly with radiation therapy is better tolerated than cisplatin given every three weeks with radiation therapy for the treatment of head and neck cancer that has spread to other places in the body (advanced). The second part of this study will also help to find out if the cisplatin given weekly approach will extend patients' life by at least the same amount of time as the cisplatin given every three weeks approach. Cisplatin is in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Radiation with low-dose cisplatin given weekly may be effective in shrinking or stabilizing head and neck cancer or preventing its recurrence.

Principal Investigator
Jennifer Dorth MD
Department/Division
Cancer (Head and Neck)
  • UH IRB: STUDY20231046 / SITE00002084
  • StudyID: NRG-HN009
  • ClinicalTrials.gov: NCT05050162
I'm Interested!
Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422